不同来源间充质干细胞外泌体在1型糖尿病治疗中的研究进展

Research progress of exosomes from different sources of mesenchymal stem cells in the treatment of type 1 diabetes mellitus

1型糖尿病(T1DM)是一种胰岛β细胞自身免疫损伤的慢性特异性疾病,目前无法治愈。间充质干细胞外泌体(MSC-Exos)是间充质干细胞通过旁分泌途径分泌的一种生物活性产物,外泌体无细胞疗法被认为是一种极具前景的替代细胞治疗方法,可能为T1DM的治疗带来新希望。MSC-Exos有多种组织来源且作用机制各有异同点,通过对不同来源MSC-Exos在T1DM治疗中的最新研究进展加以总结,以期为T1DM新的治疗策略提供支持和理论依据。

Type 1 diabetes mellitus(T1DM)is a chronic and specific disease of autoimmune damage to isletβcells that is currently incurable.Mesenchymal stem cell-derived exosomes(MSC-Exos)are biologically active products secreted by mesenchymal stem cells through the paracrine pathway.Exosome cell-free therapy is considered a promising alternative to cell-based therapy and is thought to potentially bring new hope for the treatment of T1DM.MSC-Exos have multiple tissue sources and similarities as well as differences in their mechanisms of action.The latest research progress on the use of MSC-Exos from different sources in the treatment of T1DM is summarized,with the goal of providing support and a theoretical basis for new therapeutic strategies for T1DM.